Recent News

• 03.26.2026 - Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
• 03.19.2026 - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
• 03.16.2026 - Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
• 03.01.2026 - Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
• 02.26.2026 - Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Recent Filings

• 03.20.2026 - EX-99.1 EX-99.1
• 03.20.2026 - 8-K Current report
• 03.16.2026 - 8-K Current report
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - EX-99.1 EX-99.1
• 03.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 144 Report of proposed sale of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2026 - 144 Report of proposed sale of securities